Intervention

empagliflozin

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting5
Common conditions16
Lead sponsors shown11
Advertisement

Clinical trials

15 shown
Add-on Diuretics in Acute Decompensated Heart FailureNCT07372040 · 2026-02-01
RECRUITING
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminNCT07093476 · 2025-07-18
RECRUITING
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20
RECRUITING
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart FailureNCT06507657 · 2024-12-12
RECRUITING
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17
RECRUITING
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · 2026-09-01
NOT_YET_RECRUITING
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient DepartmentNCT06683053 · 2023-03-17
ACTIVE_NOT_RECRUITING
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With PrediabetesNCT05174507 · 2022-06-24
WITHDRAWN
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With EmpagliflozinNCT05162014 · 2021-12-20
COMPLETED
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line SulfonylureasNCT05102071 · 2021-11-01
WITHDRAWN
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient SettingNCT03979352 · 2019-08-01
COMPLETED
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End ProductsNCT02768220 · 2017-12-01
WITHDRAWN
Empa PASS on Urinary Tract MalignanciesNCT03464045 · 2016-11-16
COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes MellitusNCT02863328 · 2016-08-10
COMPLETED
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II DiabeticsNCT01001962 · 2016-01-01
UNKNOWN

Trial status mix

RECRUITING5
COMPLETED4
WITHDRAWN3
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
UNKNOWN1

Phase mix

PHASE36
PHASE43
PHASE22
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.